



13th March 2024

To,

The Secretary
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street Mumbai 400 001
Scrip Code: 500674

The Secretary
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra East,
Mumbai 400 050
Symbol: SANOFI

Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“SEBI (LODR) Regulations”)

Dear Sir/Madam,

Please find enclosed a Press Release as regards to an exclusive promotion and distribution agreement between Sanofi India Limited (SIL) and Emcure Pharmaceuticals Limited for promotion and distribution of SIL’s Cardiovascular products in India for an initial period of five (5) years on terms and conditions as agreed between the Parties, effective immediately.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is for your information and records.

Thanking you,

Yours faithfully

For **Sanofi India Limited**

Radhika Shah
Company Secretary & Compliance Officer
Membership No: A19308

Encl: as above

Press Note

Sanofi India Limited and Emcure Pharmaceuticals announce exclusive distribution partnership to broaden reach of Sanofi's Cardiovascular brands

Mumbai, March 13, 2024. The Board of Directors of **Sanofi India Limited ("SIL")** today approved an exclusive distribution and promotion agreement **between SIL and Emcure Pharmaceuticals Limited ("Emcure")** for **SIL's Cardiovascular products in India**, effective immediately.

Emcure Pharmaceuticals will exclusively distribute and promote the Company's Cardiovascular (CV) range of products that include well-established brands like Cardace®, Clexane®, Targocid®, Lasix® and Lasilactone®.

While SIL will continue to own, import, and manufacture these brands across Sanofi's plants in India and internationally, Emcure will leverage its strengths to engage healthcare professionals and expand reach of these therapeutic solutions for patients who need them across all areas of India.

Sanofi India's concerned employees will have the opportunity to work at Emcure.

Mr. Rodolfo Hrosz

Managing Director, Sanofi India Limited

"Sanofi has been committed to improving lives of patients in India through its range of products. Sanofi India has many cardiovascular products which are leaders in their respective categories. With Emcure's wide presence across India, our partnership will benefit both HCPs (Healthcare Professionals) and patients by creating the opportunity to maximize the reach of our CV products."

Mr. Satish Mehta

Chief Executive Officer and Managing Director, Emcure Pharmaceuticals Limited

"At Emcure Pharmaceuticals our competitive advantage lies in our established presence in all major therapeutic areas including cardiology. We're delighted to have the opportunity to partner with Sanofi India as their range of well-established cardiovascular brands will complement our strong CV portfolio, making it a highly robust offering. Towards this endeavour, Sanofi's relevant team also has the opportunity to join us."

Sanofi continues to give fresh impetus to its business in the Country with an accelerated growth plan - 'India for India', across its pharmaceuticals, specialty, consumer healthcare and vaccines businesses.

Sanofi - in India for India

As Sanofi India, we are in a great place to make a difference. Present in India for nearly seven decades, we have earned the trust of our customers and stakeholders for our commitment to promoting health. As we chase the miracles of science to improve people's lives, we continue to engage across the entire health spectrum from prevention with vaccines to wellness, treatment, patient support & capacity building.

Our India Charitable Access Program is the country's longest running humanitarian program providing free treatment to people afflicted with Lysosomal Storage Disorders. We conduct clinical trials here so that India can have quicker access to the latest from our global pipeline. Our world-class manufacturing site in Goa produces for people in India and 60+ other countries. Recognized by the 'Top® Employers Institute' – a global authority that honours excellence in people practices – for 5 years in a row (since 2019), our local entities include Sanofi India Limited (SIL - listed entity) and Sanofi Healthcare India Pvt. Ltd. (SHIPL).

Visit us at www.sanofi.in and www.sanofiindia ltd.com, or connect with us on [LinkedIn](#) and [Twitter](#).

About Sanofi

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

About Emcure Pharmaceuticals Ltd.

Emcure Pharmaceuticals Ltd. (EPL) is an Indian pharmaceutical company headquartered in Pune engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas. Established in 1981, EPL is ranked as the 13th largest pharma company in India in terms of Domestic Sales for MAT September 2023. Emcure is present in 70+ countries globally including Europe and Canada.

To know more about Emcure, please visit: <https://www.emcure.com/>

Media Relations

Aparna Thomas | aparna.thomas@sanofi.com

||

Naveen Soni | naveen.soni@emcure.com

Agency Partner

Kritika Khatwani | kritika.khatwani@adfactorspr.com

||

Aasiya Shaikh | aasiya.shaikh@adfactorspr.com

--- ENDS HERE ---